Chen Wei's team has made new progress in nebulized inhalation of the new crown vaccine
Science and Technology Daily, Beijing, July 28 (Wang Jingyi, Wang Di, reporter Zhang Qiang) The reporter learned on the 28th from the Academy of Military Medicine of the Academy of Military Sciences that the team led by Chen Wei, an academician of the Chinese Academy of Engineering and a researcher of the Academy of Military Medicine, has developed a restructuring of aerosol inhalation. The new crown vaccine (adenovirus vector) phase I clinical trial data was published online in the international authoritative medical journal "The Lancet · Infectious Diseases" on the 26th Beijing time.
This is the first published clinical trial result of the new crown vaccine mucosal immunity in the world.
The results of the study show that the recombinant new crown vaccine for aerosol inhalation has good safety, tolerability and immunogenicity.
A dose of aerosolized inhalation vaccine requires only one-fifth of the vaccine dose intramuscularly, and the level of cellular immune response produced is equivalent to that of intramuscular injection.
Nebulized inhalation booster immunization on the 28th day after intramuscular injection of recombinant new crown vaccine can induce the production of high levels of neutralizing antibodies.
The clinical trial was launched in Wuhan on September 29, 2020. It was jointly completed by Chen Wei's team and Wuhan University Zhongnan Hospital. The phase II clinical trial is progressing in an orderly manner.
It is understood that the aerosol inhalation vaccine is the same as the recombinant new crown vaccine that has been conditionally approved for marketing in terms of formulation and production technology.
Compared with the cellular and humoral immunity formed by the injectable new crown vaccine, the nebulized vaccine can induce mucosal immunity in the human body, preventing infection and blocking transmission at the first pass of virus invasion.
The vaccinators do not need injections, but only need to inhale the vaccine into the respiratory tract and lungs through aerosol inhalation equipment, so as to obtain the "triple protection" of mucosal immunity, cellular immunity, and humoral immunity.
According to Hou Lihua, a researcher from the Academy of Military Medicine of the Academy of Military Sciences, aerosolized inhalation vaccines can be vaccinated with only one inhalation, which is safer and more convenient, and is suitable for large-scale population promotion.